Star Pharmaceuticals

What Star Pharmaceuticals does

Star Pharmaceuticals is a privately held US specialty pharmaceutical company that develops, markets, and distributes prescription and over-the-counter products targeted at urological conditions. Its entire commercial portfolio centers on a single core SKU, Uribel — a multi-ingredient capsule combining methenamine (118mg), sodium phosphate monobasic (40.8mg), phenyl salicylate (36mg), methylene blue (10mg), and hyoscyamine sulfate (0.12mg) to deliver analgesic, antispasmodic, and antiseptic activity for irritative voiding symptoms associated with lower urinary tract infections, interstitial cystitis, painful bladder syndrome, and recovery following diagnostic procedures such as cystoscopy. The technology is a proprietary combination formulation, not a novel molecular entity, and its value rests on delivering multiple mechanisms of action in one capsule.

The business operates a traditional specialty pharma distribution model. Uribel is sold through retail pharmacies in bottles of 100 (NDC 0076-0111-01) and cartons of 20 individually pouched capsules (NDC 0076-0111-02), with patient acquisition driven primarily through digital channels: the corporate website (starpharm.com), a dedicated product microsite (UribelInfo.com), and a direct-to-consumer manufacturer coupon program that brings patient out-of-pocket cost to as low as $25 per prescription (excluding Medicare/Medicaid patients). The customer base is fragmented individual patients who obtain the product via a healthcare provider's prescription; there are no disclosed institutional accounts, payer concentration, or enterprise contracts.

Star Pharmaceuticals is a US-only operation with no disclosed international presence, no funding rounds, no M&A activity, no partnerships, and no leadership-team disclosures in the available data. Ownership, founding date, and headcount are not stated; the company is privately held with no public ticker. Brand equity is concentrated in the Uribel trademark, and the company's stated differentiator is the breadth of symptom coverage delivered by its five-ingredient combination within a single capsule.

Name

Star Pharmaceuticals

Legal name

Star Pharmaceuticals

Website

https://starpharm.com

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

Star Pharmaceuticals is a privately held US specialty pharmaceutical company that develops, markets, and distributes a single core product, Uribel — a multi-ingredient prescription capsule for patients with irritative voiding symptoms from UTIs, interstitial cystitis, painful bladder syndrome, or post-procedure recovery, sold through retail pharmacies and DTC coupon programs.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals (Urological)

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro industry

PRIMARYHLAIAAAM

Nephrology & Urology Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

SECONDARYHLAIACAH

Nephrology & Urology Specialty Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Specialty Pharmaceuticals

Keywords

• Specialty pharmaceuticals
• Urological therapies
• Prescription medications
• OTC pharmaceuticals
• Multi-ingredient formulations

Headquarters

HQ city

Fort Lauderdale

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Technology or R&D, Marketing or Sales, Personnel

Revenue model

1. Pharmaceutical Product Sales: Star Pharmaceuticals generates revenue through the development, marketing, and distribution of prescription and over-the-counter (OTC) pharmaceutical products. Their primary product Uribel is available by prescription and potentially OTC, sold through pharmacies to consumers.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

Star Pharmaceuticals is a specialty pharmaceutical company that develops, markets, and distributes prescription and over-the-counter (OTC) pharmaceutical products. Its featured offering is Uribel, a multi-ingredient capsule therapy containing methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate, sold through retail pharmacies for the treatment of irritative voiding symptoms associated with urinary tract infections, interstitial cystitis, painful bladder syndrome, and post-diagnostic procedure discomfort.

Product overview

Star Pharmaceuticals is a specialty pharmaceutical company that develops, markets, and distributes prescription and over-the-counter (OTC) products. The company offers a single core product, Uribel capsules, a multi-ingredient therapy combining analgesic, antispasmodic, and antiseptic ingredients for the treatment of irritative voiding symptoms associated with urinary tract conditions and diagnostic procedures.

Differentiator

Problem solved

Functional benefit

Brands

• Uribel: Uribel is a multi-ingredient prescription therapy for the treatment of local symptoms associated with irritative voiding, such as inflammation, hypermotility, and pain accompanying urinary tract infections. It contains methenamine, sodium phosphate monobasic, phenyl salicylate, methylene blue, and hyoscyamine sulfate.

Products and services

• Uribel Uribel is a multi-ingredient prescription/OTC capsule therapy for the treatment of local symptoms associated with irritative voiding, including inflammation, hypermotility, and pain accompanying lower urinary tract infections, interstitial cystitis, painful bladder syndrome, and post-diagnostic procedures. It contains methenamine 118mg, sodium phosphate monobasic 40.8mg, phenyl salicylate 36mg, methylene blue 10mg, and hyoscyamine sulfate 0.12mg, and is available in bottles of 100 (NDC 0076-0111-01) and cartons of 20 individually pouched capsules (NDC 0076-0111-02).

Quantifiable outcome

• 70%-90% of methenamine hydrolyzed in acidic urine
• +1 more outcomes

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Recent moves4 records

Expansion highlights3 records

Direct peers

• ANI Pharmaceuticals: Specialty pharmaceutical company that markets branded and generic products in therapeutic areas including urology. Comparable as a small-cap specialty pharma that develops, markets, and distributes niche prescription products through retail and specialty pharmacy channels.
• Mission Pharmacal (Validus Pharmaceuticals): A privately held specialty pharmaceutical company focused on urology and women's health, historically associated with the Uribel brand. Highly comparable business model: small specialty pharma marketing branded urology products through retail pharmacy channels with DTC support.
• Ferring Pharmaceuticals: Specialty pharmaceutical company with a strong urology and reproductive health focus, marketing branded prescription therapies for bladder and urinary tract conditions. Comparable as a specialty pharma peer targeting urologists and the same irritative voiding / bladder symptom patient population.
• Upsher-Smith Laboratories: Privately held specialty pharmaceutical company marketing branded prescription products across multiple therapeutic categories including urology. Comparable business profile: mid-sized specialty pharma with a portfolio of niche, often legacy, prescription products distributed through retail pharmacies.

Broad incumbents

• Pfizer: Global pharmaceutical major with historical and current urology franchises (e.g., treatments for OAB and UTIs). Comparable as a broad incumbent whose products may compete with or substitute for Uribel in the same prescriber channels, though Pfizer's portfolio and scale are vastly larger.
• Amneal Pharmaceuticals: U.S. specialty and generic pharmaceutical company with a urology and anti-infective portfolio including products for urinary tract conditions. Comparable as a larger incumbent competing in the same UTI/urology therapeutic categories through retail pharmacy distribution.
• Teva Pharmaceutical Industries: Global pharmaceutical company with a broad urology and women's health portfolio including therapies for overactive bladder and urinary conditions. Comparable as a broad incumbent operating in the same therapeutic space though at vastly greater scale and with a wider product portfolio.
• Aurobindo Pharma USA: Large generic and specialty pharmaceutical manufacturer with a substantial urology and anti-infective portfolio including products used in UTI management. Comparable as a competitor in the same therapeutic categories (UTI/urology symptom relief) though operating at much greater scale and primarily in generics.
• Astellas Pharma: Global pharmaceutical company with a leading urology franchise including treatments for overactive bladder and interstitial cystitis / painful bladder syndrome. Directly comparable because PBS/IC are among Uribel's target indications, and Astellas actively competes for the same urology prescriber audience.

Emerging players

• Viveve Medical: Smaller emerging medtech/specialty player addressing urinary incontinence and pelvic health conditions. Comparable as a niche company addressing overlapping patient populations (women with urinary/pelvic symptoms) though operating in device rather than pharmaceutical therapy.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Star Pharmaceuticals